: We report herein the successful perioperative management of a 57-year-old man with a type I Glanzmann thrombasthenia undergoing coronary artery bypass graft surgery and right carotid endarterectomy. The patient suffered from several lesions in the three major coronary arteries and in the right carotid necessitating surgery. Prophylactic human leukocyte antigen (HLA)-matched platelets transfusions were continuous administrated before, and through the immediate perioperative period. Posttransfusion platelet recovery was monitored using flow cytometry to determine the percentage of circulating platelet expressing CD61 (β3). No bleeding complications occurred during and following the procedure. The patient did not develop HLA antibodies or αIIbβ3 antibodies. Thrombophilia screening revealed a heterozygous G20210A prothrombin gene mutation. The patient also suffered from an atrial fibrillation, necessitating anticoagulation therapy. During the hospital stay, a treatment with vitamin K antagonists for stroke prevention was initiated. The patient was discharged 8 days following surgery, and no further complications occurred during the 6 months follow-up.
Background: post-injury acquired immunodepression (AID) is frequently assessed by the diminished expression of Human Leukocyte Antigen-D Related on circulating monocytes (mHLA-DR). The relation with mortality and the occurrence of ICU-acquired infections (IAI) requires confirmation in large cohorts of patients. This study tested in a large number of ICU patients from a single center the association of mHLA-DR with mortality and secondary infections. Methods: This prospective, observational study in a surgical ICU of a French tertiary hospital reports mHLA-DR measurements (fixed flow cytometry protocol) done 1st within the 3 days post-admission and 2nd after the 7th day. The other collected parameters were: the SAPS II and SOFA scores, sex, age, comorbidity, mortality and ICU-acquired infections. The associations between mHLA-DR and outcomes were tested by adjusted Fine and Gray sub-distribution competing risk models. Findings: 1053 patients were subdivided into 4 subgroups depending on the main motif for admission. Overall, 151 patients (14.3%) died in the ICU with an independent association with the amplitude of the first mHLA-DR decrease (HR = 0.71 [0.57; 0.95], p < 0.01); 592 patients had a 2nd mHLA-DR measurement of whom 223 patients (37.7%) complicated by IAI. These patients had a lower mHLA-DR than other patients (mHLA-DR = 9.0 log vs. 9.3 log, p < 0.01). IAI occurrence was independently associated with first, the 2nd mHLA-DR level regardless the initial severity (HR = 0.66 [0.51; 0.84], p = 0.001) and second, with the slope between the 1st and 2nd values (HR = 0.62 [0.43; 0.89], p = 0.009). Interpretation: the association between the early mHLA-DR expression and ICU mortality does not improve the prediction given by the severity scores. The persistence or a decrease of low mHLA-DR expression are independent and reliable predictors of ICU-acquired infection. Funding: no financial interest
1 October 2021 in Archives of Cardiovascular Diseases